News

Believing that stress or genetics play roles in the development of Alzheimer’s increases people’s fear that the disease will strike them, according to a study. The research, “The Influence of Psychosocial and Cognitive Factors on Perceived Threat of Alzheimer’s Disease,” also revealed that cognition problems, a feeling that…

A high-fat, high-sugar diet may increase the risk of Alzheimer’s disease in people carrying the ApoE4 gene, according to a new study, “Obesity Accelerates Alzheimer-Related Pathology in APOE4 but Not APOE3 Mice,” that appeared in the journal eNeuro. Obesity is considered an environmental risk factor for Alzheimer’s, while the strongest genetic…

Higher levels of a molecule called anthranilic acid could signal that a person is at increased risk of developing dementia and Alzheimer’s disease, according to a study. The research, “Association of amine biomarkers with incident dementia and Alzheimer’s disease in the Framingham Study,” was published in the journal…

The advances scientists have made in identifying dementia symptoms include the hallmarks of Lewy body dementia, the third most prevalent kind behind Alzheimer’s and vascular dementia. Scientists have also discovered biomarkers for diagnosing the disease, including the presence of the protein aggregates known as Lewy bodies that give the condition…

Anavex Life Sciences  has presented new information at a New York conference on Anavex 2-73, which prevented further decline in Alzheimer’s patients’ mental capacity in a clinical trial last year. Dr. Christopher U. Missling, Anavex’s president and chief executive officer, made the presentation at the Jefferies 2017 Global…

The $100 million IDEAS (Imaging Dementia — Evidence for Amyloid Scanning) Study is working closely with researchers and government officials to add three additional studies to the main project, where more than 18,000 people with cognitive deterioration but whose diagnosis is unclear are receiving a brain amyloid PET…

Lundbeck, a global pharmaceutical company specializing in therapies for neurological disorders, has obtained the rights to IBC’s (ImmunoBrain Checkpoint) groundbreaking research into treatment for Alzheimer’s disease. “IBC has a unique and innovative approach to this highly complex disease and the data generated until now are highly promising,” Jacob Tolstrup,…

A new study found personalized music and memory therapy helped decrease antipsychotic and anti-anxiety medication use, as well as improve dementia symptoms, in people living with Alzheimer’s disease (AD) and related dementias (ADRD). Results from the study were published online in the American Journal of Geriatric Psychiatry, under the…

The National Institutes of Health (NIH) has awarded Pain Therapeutics a $1.7 million research grant to study PTI-125 as a potential treatment for Alzheimer’s disease. PTI-125 is an oral, small molecule drug developed by the Austin, Texas-based company in collaboration with other partners. It has been shown to significantly improve…

Insightec’s new platform, Exablate Neuro, is to be a part of the first-ever clinical trial (NCT02986932) evaluating the safety and feasibility of opening the blood-brain barrier (BBB) in Alzheimer’s disease patients at Sunnybrook Health Sciences Centre in Toronto, Canada. Exablate Neuro uses a technique called…